A meta-analysis on randomized controlled trials of statins to prevent atrial fibrillation

Chinese Journal of Evidence-Based Medicine

Volumn 9, Issue 5, 2009, Pages 570-573

  Shi, Wei ^a   Liu, Zeng Zhang ^a   Su, Li ^a   Yin, Yue Hui ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Meta analysis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 69149094340     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Moher D, Schulz KF, Altman D. CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallelgroup randomized trials. JAMA, 2001, 285(15): 1987-1991. (Pubitemid 32366951)
2. Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
3. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation After electrical cardioversion. Am J Cardiol, 2004, 93(6): 780-782. (Pubitemid 38338579)
4. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J, 2005, 150(5): 1064. (Pubitemid 41613720)
5. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation After electrical cardioversion. Am J Cardiol, 2006, 97(10): 1490-1493.
6. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 2006, 114(14): 1455-1461. (Pubitemid 44526999)
7. Lijnen P, Celis H, Fagard R, et al. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens, 1994, 12(1): 59-64. (Pubitemid 24044009)
8. Tesfamariam B, Frohlich BH, Gregg RE, et al. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol, 1999, 34(1): 95-101. (Pubitemid 29296143)
9. Bolotina V, Omelyanenko V, Heyes B, et al. Variations of membrane cholesterol alter the kinetics of Ca2+-dependent K+ channels and membrane fluidity in vascular smooth muscle cells. Pflugers Arch, 1989, 415(3): 262-268. (Pubitemid 20012724)
10. Engelmann M, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J, 2005, 26(20): 2083-2092. (Pubitemid 41408600)
11. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res, 2004, 62(1): 105-111. (Pubitemid 38326816)
12. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002,105 (7): 868-873. (Pubitemid 34174929)
13. Porter KE, Turner NA, O'Regan DJ, et al. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res, 2004, 61(4): 745-755.
14. Shiroshita-Takeshita A, Schram G, Lavoie J, et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation, 2004, 110(16): 2313-2319. (Pubitemid 39407332)
15. Pliquett RU, Cormish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation, 2003, 107(19): 2493-2498.
16. Welzig CM, Shin DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation, 2003, 108(22): 2743-2746.